Tonix Pharmaceuticals Holding Corp [TNXP] stock is trading at $0.35, up 0.44%. An important factor to consider is whether the stock is rising or falling in short-term value. The TNXP shares have gain 7.79% over the last week, with a monthly amount glided 9.36%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 21, March 2024, Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting. In a post published today on Yahoo Finance, Four Phase 2 investigator-initiated studies of TNX-1900 (intranasal potentiated oxytocin) are ongoing for pediatric obesity, binge eating disorder, bone health in autism and social anxiety disorder.
From an analyst’s perspective:
Previously, ROTH Capital upgraded its rating to Buy on April 18, 2019, and kept the price target unchanged to $4. On August 18, 2017, upgrade upgraded it’s rating to Buy but maintained its price target of $6 on the stock. ROTH Capital downgraded its rating to a Neutral. Oppenheimer reiterated its recommendation of a Outperform and reduced its price target to $10 on February 17, 2016. In a note dated June 12, 2015, Oppenheimer initiated an Outperform rating and provided a target price of $18 on this stock.
Tonix Pharmaceuticals Holding Corp [TNXP] stock has fluctuated between $0.26 and $4.00 over the past year. Tonix Pharmaceuticals Holding Corp [NASDAQ: TNXP] shares were valued at $0.35 at the most recent close of the market.
Analyzing the TNXP fundamentals
Gross Profit Margin for this corporation currently stands at 0.13% with Operating Profit Margin at -3.27%, Pretax Profit Margin comes in at -3.19%, and Net Profit Margin reading is -3.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.9, Equity is -0.79 and Total Capital is -1.02. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.3326 points at the first support level, and at 0.3192 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.3582, and for the 2nd resistance point, it is at 0.3704.
Tonix Pharmaceuticals Holding Corp [TNXP] reported earnings per share of -$1.83 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.49/share, meaning a difference of $-0.34 and a surprise factor of -22.80%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$2.68 per share as compared to estimates of -$2.75 per share, a difference of $0.07 representing a surprise of 2.50%.
Ratios To Look Out For
For context, Tonix Pharmaceuticals Holding Corp’s Current Ratio is 1.77. On the other hand, the Quick Ratio is 1.02, and the Cash Ratio is 0.39. Considering the valuation of this stock, the price to sales ratio is 7.01, the price to book ratio is 0.05.
